A Phase 1 interventional study of Apremilast and Rifampin Oral Capsules in Healthy Subjects, sponsored by Amgen. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-06-09.
Sponsored by Amgen · Phase 1, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to evaluate how the pharmacokinetics of apremilast may be affected by a single intravenous dose of rifampin and multiple oral doses of rifampin.
Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.
Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received the following 3 treatment regimens: * A single oral dose of 30 mg apremilast on Day 1 (Period 1); * A single oral dose of 30 mg apremilast followed 5 minutes later by a 30-minute intravenous infusion of 600 mg rifampin on Day 5 (Period 2); * Once daily oral doses of 600 mg rifampin for 15 days (from Day 7 to Day 21) with a single oral dose of 30 mg apremilast co-administered with the rifampin dose on Day 20 (Period 3).
Drug: Apremilast · Drug: Rifampin Oral Capsules · Drug: Rifampin IV Solution
Tablets for oral administration
Also known as: CC-10004, Otezla®
Capsules for oral administration
Also known as: RIFADIN™
Intravenous (IV) solution
Also known as: RIFADIN™
Area Under the Plasma Concentration-time Curve From Time Zero to the Last Quantifiable Concentration (AUCt) of Apremilast
Plasma concentrations of apremilast were determined by means of a validated, sensitive, and specific high performance liquid chromatography/tandem mass spectrometric (LC-MS/MS) assay.
Time frame: Pre-dose and at 0.5, 1, 1.5, 2, 3, 5, 8, 12, 16, 24, 36, and 48 hours following apremilast dosing on Days 1, 5, and 20
Area Under the Plasma Concentration-time Curve From Time Zero Extrapolated to Infinity (AUC∞) of Apremilast
Plasma concentrations of apremilast were determined by means of a validated, sensitive, and specific high performance liquid chromatography/tandem mass spectrometric (LC-MS/MS) assay.
Time frame: Pre-dose and at 0.5, 1, 1.5, 2, 3, 5, 8, 12, 16, 24, 36, and 48 hours following apremilast dosing on Days 1, 5, and 20
Maximum Observed Plasma Concentration (Cmax) of Apremilast
Plasma concentrations of apremilast were determined by means of a validated, sensitive, and specific high performance liquid chromatography/tandem mass spectrometric (LC-MS/MS) assay.
Time frame: Pre-dose and at 0.5, 1, 1.5, 2, 3, 5, 8, 12, 16, 24, 36, and 48 hours following apremilast dosing on Days 1, 5, and 20
Time to Maximum Observed Plasma Concentration (Tmax) of Apremilast
Plasma concentrations of apremilast were determined by means of a validated, sensitive, and specific high performance liquid chromatography/tandem mass spectrometric (LC-MS/MS) assay.
Time frame: Pre-dose and at 0.5, 1, 1.5, 2, 3, 5, 8, 12, 16, 24, 36, and 48 hours following apremilast dosing on Days 1, 5, and 20
Estimate of the Terminal Elimination Half-life (T1/2) of Apremilast in Plasma
Plasma concentrations of apremilast were determined by means of a validated, sensitive, and specific high performance liquid chromatography/tandem mass spectrometric (LC-MS/MS) assay.
Time frame: Pre-dose and at 0.5, 1, 1.5, 2, 3, 5, 8, 12, 16, 24, 36, and 48 hours following apremilast dosing on Days 1, 5, and 20
Apparent Total Plasma Clearance (CL/F) of Apremilast
Plasma concentrations of apremilast were determined by means of a validated, sensitive, and specific high performance liquid chromatography/tandem mass spectrometric (LC-MS/MS) assay.
Time frame: Pre-dose and at 0.5, 1, 1.5, 2, 3, 5, 8, 12, 16, 24, 36, and 48 hours following apremilast dosing on Days 1, 5, and 20
Apparent Volume of Distribution (Vz/F) of Apremilast
Plasma concentrations of apremilast were determined by means of a validated, sensitive, and specific high performance liquid chromatography/tandem mass spectrometric (LC-MS/MS) assay.
Time frame: Pre-dose and at 0.5, 1, 1.5, 2, 3, 5, 8, 12, 16, 24, 36, and 48 hours following apremilast dosing on Days 1, 5, and 20
This study was conducted at one clinical site in Overland Park, Kansas, USA.
| Milestone | Apremilast and Rifampin |
|---|---|
| Started | 21 |
| Received period 1 treatment | 21 |
| Received period 2 treatment | 20 |
| Received period 3 treatment | 20 |
| Completed | 20 |
| Not completed | 1 |
| Withdrew: Adverse event | 1 |
Plasma concentrations of apremilast were determined by means of a validated, sensitive, and specific high performance liquid chromatography/tandem mass spectrometric (LC-MS/MS) assay.
| ng*h/mL | Apremilast Alone | Apremilast + IV Rifampin | Apremilast + Multiple Dose Oral Rifampin |
|---|---|---|---|
| Area Under the Plasma Concentration-time Curve From Time Zero to the Last Quantifiable Concentration (AUCt) of Apremilast | 3070 ± 31.3 | 2940 ± 31.3 | 850 ± 33.7 |
Plasma concentrations of apremilast were determined by means of a validated, sensitive, and specific high performance liquid chromatography/tandem mass spectrometric (LC-MS/MS) assay.
| ng*h/mL | Apremilast Alone | Apremilast + IV Rifampin | Apremilast + Multiple Dose Oral Rifampin |
|---|---|---|---|
| Area Under the Plasma Concentration-time Curve From Time Zero Extrapolated to Infinity (AUC∞) of Apremilast | 3120 ± 31.5 | 2980 ± 31.2 | 869 ± 32.9 |
Plasma concentrations of apremilast were determined by means of a validated, sensitive, and specific high performance liquid chromatography/tandem mass spectrometric (LC-MS/MS) assay.
| ng/mL | Apremilast Alone | Apremilast + IV Rifampin | Apremilast + Multiple Dose Oral Rifampin |
|---|---|---|---|
| Maximum Observed Plasma Concentration (Cmax) of Apremilast | 290 ± 24.5 | 331 ± 25.1 | 166 ± 23.2 |
Plasma concentrations of apremilast were determined by means of a validated, sensitive, and specific high performance liquid chromatography/tandem mass spectrometric (LC-MS/MS) assay.
| hours | Apremilast Alone | Apremilast + IV Rifampin | Apremilast + Multiple Dose Oral Rifampin |
|---|---|---|---|
| Time to Maximum Observed Plasma Concentration (Tmax) of Apremilast | 2.00 (0.50 to 5.00) | 1.50 (0.50 to 5.00) | 1.00 (0.50 to 5.00) |
Plasma concentrations of apremilast were determined by means of a validated, sensitive, and specific high performance liquid chromatography/tandem mass spectrometric (LC-MS/MS) assay.
| hours | Apremilast Alone | Apremilast + IV Rifampin | Apremilast + Multiple Dose Oral Rifampin |
|---|---|---|---|
| Estimate of the Terminal Elimination Half-life (T1/2) of Apremilast in Plasma | 8.12 ± 14.1 | 7.35 ± 18.5 | 6.13 ± 24.8 |
Plasma concentrations of apremilast were determined by means of a validated, sensitive, and specific high performance liquid chromatography/tandem mass spectrometric (LC-MS/MS) assay.
| L/h | Apremilast Alone | Apremilast + IV Rifampin | Apremilast + Multiple Dose Oral Rifampin |
|---|---|---|---|
| Apparent Total Plasma Clearance (CL/F) of Apremilast | 9.60 ± 31.5 | 10.1 ± 31.2 | 34.5 ± 32.9 |
Plasma concentrations of apremilast were determined by means of a validated, sensitive, and specific high performance liquid chromatography/tandem mass spectrometric (LC-MS/MS) assay.
| liters | Apremilast Alone | Apremilast + IV Rifampin | Apremilast + Multiple Dose Oral Rifampin |
|---|---|---|---|
| Apparent Volume of Distribution (Vz/F) of Apremilast | 112 ± 35.8 | 107 ± 43.4 | 305 ± 51.6 |
Collected over Period 1 (Apremilast Alone): Day 1 to day 4; Period 2 (Apremilast + IV Rifampin): Day 5 to day 6; Period 3 (Apremilast + Multiple Dose Oral Rifampin): Day 7 up to day 32; Overall Study (All Treatment Regimens): Up to 32 days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Apremilast Alone | — | 0/21 (0%) | 2/21 (9.5%) |
| Apremilast + IV Rifampin | — | 0/20 (0%) | 4/20 (20%) |
| Apremilast + Multiple Dose Oral Rifampin | — | 0/20 (0%) | 9/20 (45%) |
| Overall Study - All Treatment Regimens | — | 0/21 (0%) | 12/21 (57.1%) |
| Event | Apremilast Alone | Apremilast + IV Rifampin | Apremilast + Multiple Dose Oral Rifampin | Overall Study - All Treatment Regimens |
|---|---|---|---|---|
| HEADACHENervous system disorders | 2/21 | 1/20 | 1/20 | 4/21 |
| RHINITISInfections and infestations | 0/21 | 0/20 | 2/20 | 2/21 |
| CONJUNCTIVAL HYPERAEMIAEye disorders | 0/21 | 1/20 | 0/20 | 1/21 |
| ABDOMINAL PAIN LOWERGastrointestinal disorders | 0/21 | 0/20 | 1/20 | 1/21 |
| ABDOMINAL PAIN UPPERGastrointestinal disorders | 0/21 | 1/20 | 0/20 | 1/21 |
| DIARRHOEAGastrointestinal disorders | 0/21 | 1/20 | 1/20 | 1/21 |
| DYSPHAGIAGastrointestinal disorders | 0/21 | 0/20 | 1/20 | 1/21 |
| ASTHENIAGeneral disorders | 0/21 | 0/20 | 1/20 | 1/21 |
| CHILLSGeneral disorders | 0/21 | 0/20 | 1/20 | 1/21 |
| FEELING HOTGeneral disorders | 0/21 | 0/20 | 1/20 | 1/21 |
| Age, Continuous(years) | Apremilast and Rifampin |
|---|---|
| Mean | 34 ± 9.6 |
| Sex: Female, Male(Participants) | Apremilast and Rifampin |
|---|---|
| Female | 1 |
| Male | 20 |
| Ethnicity (NIH/OMB)(Participants) | Apremilast and Rifampin |
|---|---|
| Hispanic or Latino | 1 |
| Not Hispanic or Latino | 20 |
| Unknown or Not Reported | 0 |
| Race/Ethnicity, Customized(Participants) | Apremilast and Rifampin |
|---|---|
| White | 12 |
| Black or African American | 9 |
| Body Mass Index (BMI)(kg/m²) | Apremilast and Rifampin |
|---|---|
| Mean | 29.14 ± 2.974 |
Plan to share: Yes — De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.
Access criteria: Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors. If not approved, a Data Sharing Independent Review Panel will arbitrate and make the final decision. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the URL below.
Data sharing details ↗ · www.amgen.com
Ran from Feb 2012 to primary completion in Apr 2012, 2 months.
Results were first posted in Jun 2021, 9 years 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Apremilast